Cure My Disease

Don't miss your cure!

 Log in / Sign up

Play therapy may boost social skills in infants with tuberous sclerosis — a trial puts it to the test

NCT ID NCT02687633

Symptom relief Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial tests whether JASPER, a play-based behavioral intervention, can improve social communication and play skills in infants (12–36 months) with tuberous sclerosis complex (TSC). Caregivers learn strategies during daily and weekly sessions to support their child's development. The study measures changes in joint engagement and attention over six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) — a play-based behavioral intervention
What this could lead to
If effective, this approach could offer a non-drug way to boost social communication and play skills in young children with tuberous sclerosis complex.
What could go wrong
This is a very small, early-stage trial with only 8 participants, so results may not apply broadly. The intensive daily sessions may be challenging for families.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

8 people

The number who actually took part.

Start date

Sep 2015

Finished

Aug 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 36 months

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * A confirmed diagnosis of Tuberous Sclerosis Complex Exclusion Criteria: * A mental age less than 6 months. A plan for epilepsy surgery during the study participation period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Tuberous sclerosis complex are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

tuberous sclerosis tuberous sclerosis 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Tuberous sclerosis complex

Contacts and locations

Locations

  • UCLA Semel Insitute

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.